文献速递糖尿病

妊娠期口服葡萄糖耐量试验结果可个体化预测未来2型糖尿病风险

Oral Glucose Tolerance Test Results in Pregnancy Can Be Used to Individualize the Risk of Future Maternal Type 2 Diabetes Mellitus in Women With Gestational Diabetes Mellitus.
PubMed 文献 · Diabetes Care · 2021-06-15

该研究基于加拿大安大略省2007-2017年55,361名初产单胎活产孕妇的回顾性队列,评估妊娠期糖尿病(GDM)女性未来发生2型糖尿病(T2DM)的风险。结果显示,GDM女性未来T2DM风险随75-g OGTT异常值数量增加而升高,3项异常者风险最高(aHR 24.57),且异常空腹血糖者风险高于异常2小时血糖者;采用加拿大糖尿病(DC)标准诊断的GDM风险高于IADPSG标准。

要点

  • GDM女性未来T2DM风险随OGTT异常值数量增加而升高,3项异常者aHR达24.57。
  • 异常空腹血糖者未来T2DM风险最高(aHR 14.09),异常2小时血糖者最低(aHR 9.22)。
  • 采用DC标准诊断的GDM未来T2DM发生率高于IADPSG标准(18.74 vs. 14.07/1000人年)。

核心结论

  • 对于GDM女性,可根据OGTT异常值的类型和数量以及诊断标准个体化提供未来T2DM风险信息。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入2007-2017年加拿大安大略省所有接受75-g OGTT筛查GDM的初产单胎活产孕妇,共55,361名。
  • 中位随访4.4年(四分位距2.8-6.3,最长10.3年)。

主要发现

  • 无GDM女性未来T2DM发生率为2.18/1000人年。
  • GDM女性未来T2DM发生率:DC标准18.74(95% CI 17.58-19.90)/1000人年,IADPSG标准14.07(95% CI 13.24-14.91)/1000人年。
  • 3项OGTT异常者未来T2DM发生率49.93/1000人年,aHR 24.57(95% CI 21.26-28.39)。
  • 异常空腹血糖者aHR 14.09(95% CI 12.46-15.93),异常2小时血糖者aHR 9.22(95% CI 8.19-10.37)。
  • 以指数妊娠后5年固定时间点T2DM风险为结局时,观察到相似结果。

关键数值与推荐

  • GDM诊断标准:Diabetes Canada(DC)与IADPSG标准。
  • OGTT异常值数量分层:1项、2项、3项异常。
  • OGTT异常值类型分层:空腹、1小时、2小时异常。

临床怎么用

  • 对GDM女性,应结合OGTT异常值的类型和数量以及所用诊断标准评估未来T2DM风险。
  • OGTT异常值数量多、尤其空腹血糖异常者,未来T2DM风险更高,可能需要更密切的随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to quantify the risk of future maternal type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) based on the type and number of abnormal 75-g oral glucose tolerance test (OGTT) values and the diagnostic criteria used for the diagnosis of GDM. RESEARCH DESIGN AND METHODS: We conducted a population-based retrospective cohort study of all nulliparous women with a live singleton birth who underwent testing for GDM using a 75-g OGTT in Ontario, Canada (2007-2017). We estimated the incidence rate (per 1,000 person-years), overall risk (expressed as adjusted hazard ratio [aHR]), and risk at 5 years after the index pregnancy of future maternal T2DM. Estimates were stratified by the type and number of abnormal OGTT values, as well as by the diagnostic criteria for GDM (Diabetes Canada [DC] vs. International Association of the Diabetes and Pregnancy Study Groups [IADPSG] criteria). RESULTS: A total of 55,361 women met the study criteria. The median duration of follow-up was 4.4 (interquartile range 2.8-6.3; maximum 10.3) years. Using women without GDM as reference (incidence rate 2.18 per 1,000 person-years), women with GDM were at an increased risk of future T2DM; this risk was greater when using the DC compared with the IADPSG criteria (incidence rate 18.74 [95% CI 17.58-19.90] vs. 14.07 [95% CI 13.24-14.91] per 1,000 person-years, respectively). The risk of future maternal T2DM increased with the number of abnormal OGTT values and was highest for women with three abnormal values (incidence rate 49.93 per 1,000 person-years; aHR 24.57 [95% CI 21.26-28.39]). The risk of future T2DM was also affected by the type of OGTT abnormality: women with an abnormal fasting value had the greatest risk, whereas women with an abnormal 2-h value had the lowest risk (aHR 14.09 [95% CI 12.46-15.93] vs. 9.22 [95% CI 8.19-10.37], respectively). Similar findings to those described above were observed when the risk of T2DM at a fixed time point of 5 years after the index pregnancy was considered as the outcome of interest. CONCLUSIONS: In women with GDM, individualized information regarding the future risk of T2DM can be provided based on the type and number of abnormal OGTT values, as well as the diagnostic criteria used for the diagnosis of GDM.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Hiersch L, Shah BR, Berger H, et al. Oral Glucose Tolerance Test Results in Pregnancy Can Be Used to Individualize the Risk of Future Maternal Type 2 Diabetes Mellitus in Women With Gestational Diabetes Mellitus. Diabetes Care. 2021. PMID: 34131049. doi:10.2337/dc21-0659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。